Cardlytics, Inc. - Common Stock, par value $0.0001 (CDLX)

Q3 2021 13F Holders as of 30 Sep 2021

Type / Class
Equity / Common Stock, par value $0.0001
Shares outstanding
53,041,500
Number of holders
162
Total 13F shares, excl. options
31,254,515
Shares change
-150,309
Total reported value, excl. options
$2,624,187,470
Value change
-$77,766,844
Put/Call ratio
231%
Number of buys
75
Number of sells
-100
Price
$83.94

Significant Holders of Cardlytics, Inc. - Common Stock, par value $0.0001 (CDLX) as of Q3 2021

220 filings reported holding CDLX - Cardlytics, Inc. - Common Stock, par value $0.0001 as of Q3 2021.
Cardlytics, Inc. - Common Stock, par value $0.0001 (CDLX) has 162 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 31,254,515 shares of 53,041,500 outstanding shares and own 58.9% of the company stock.
Largest 10 shareholders include CAS Investment Partners, LLC (5,149,591 shares), WELLINGTON MANAGEMENT GROUP LLP (3,795,320 shares), VANGUARD GROUP INC (2,884,810 shares), BlackRock Inc. (2,469,593 shares), JPMORGAN CHASE & CO (1,837,247 shares), 683 Capital Management, LLC (1,465,219 shares), Alua Capital Management LP (1,244,259 shares), KPS Global Asset Management UK Ltd (1,176,830 shares), MORGAN STANLEY (934,559 shares), and BAILLIE GIFFORD & CO (745,804 shares).
This table shows the top 162 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
Investor Option Weight % Change % Value $ * Price $ Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.